ArticleParasite (Paris, France)2025
The impact of schistosomiasis on the Global Disease Burden: a systematic analysis based on the 2021 Global Burden of Disease study.
Article in Parasite (Paris, France), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of rapid and point-of-care tests forFrontiers in parasitology · 2026Pooled it
- Development and field evaluation of a multiplex qPCR assay for environmental DNA detection of Schistosoma mekongi and its intermediate snail host Neotricula aperta in the Mekong River Basin.Infectious diseases of poverty · 2026Article
- Government health care worker training needs for intestinal schistosomiasis morbidity management.PLoS neglected tropical diseases · 2026Article
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Novel 1ACS infectious diseases · 2026Article
- Diseases Caused by Parasites with Invertebrate Hosts in China: Burden and Trends of Leishmaniasis and Schistosomiasis.Pathogens (Basel, Switzerland) · 2026Article
- Schistosomiasis in Yemen: Focal Persistence, Possible Resurgence, and Challenges to Elimination.Research and reports in tropical medicine · 2026Review
- Prognostic determinants and mortality risk of advanced schistosomiasis revealed by Lasso-Cox regression integrative approach.PLoS neglected tropical diseases · 2026Article
- Sex in Immune Cells and Parasitic Diseases - A Complex Relationship.Immunological reviews · 2026Review
- Host genetic background influences the severity of disease in Schistosoma haematobium infections.Parasite (Paris, France) · 2026Article
- Burden of anaemia in displaced women and children in refugee settings worldwide, update for 2017-2024: a cross-sectional study.BMJ open · 2025Article
- Global Epidemiology of Vector-Borne Parasitic Diseases: Burden, Trends, Disparities, and Forecasts (1990-2036).Pathogens (Basel, Switzerland) · 2025Article
- Zoonotic diseases in China: epidemiological trends, incidence forecasting, and comparative analysis between real-world surveillance data and Global Burden of Disease 2021 estimates.Infectious diseases of poverty · 2025Article
- Performance (Sensitivity and Specificity) of a New Point-of-Care Immunochromatography to Screen for Imported Chronic Schistosomiasis Among Long-Term Sub-Saharan Migrants.Open forum infectious diseases · 2025Article
- A model predicting the 6-year all cause mortality of patients with advanced schistosomiasis after discharge: Derived from a large population-based cohort study.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Schistosomiasis is a neglected tropical disease that causes a significant global burden. The aim of this study was to report the latest estimates of the global, regional, and national schistosomiasis disease burden and forecast changes in schistosomiasis-related disease burden. This work was based on the 2021 Global Burden of Disease (GBD) study. We analyzed the schistosomiasis data by sex, age in years, and Socio-Demographic Index (SDI) region and country, using Age-Standardized Rates (ASR) for comparisons among different groups. The Estimated Annual Percent Changes (EAPC) analysis was used to evaluate the temporal trend of the disease burden, and the Differential Autoregressive Integrated Moving Average (ARIMA) and Exponential Smoothing (ES) models were used to predict the disease burden from 2022 to 2046. In the GBD 2021 study, it was reported that compared to 1990, the number of deaths has decreased by 74,350, the prevalence number has increased by 1,482,260, and Disability-Adjusted Life Years (DALYs) have decreased by 1,770,436. Additionally, the age-standardized mortality rate (ASMR) has decreased by 0.31 per 100,000 people, with an EAPC of -0.353 (95% CI: -0.361 to -0.344). Similarly, the age-standardized DALYs rate (ASDR) has decreased by 15.45 per 100,000 people (EAPC: -1.56, 95% CI: -1.78 to -1.34), and the age-standardized prevalence rate (ASPR) has decreased by 559.64 per 100,000 people (EAPC: -0.63, 95% CI: -0.95 to -0.31). The regions and countries with the highest disease burden are mostly concentrated in Africa. Despite a general decline in global schistosomiasis burden indicators, the burden of disease has actually increased in high SDI areas. The ARIMA and ES models forecast results show that female mortality and ASMR will decline in the next 25 years, while male mortality and ASMR will remain stable, and other disease indicators will continue to decline. The global schistosomiasis burden has significantly decreased over the past 30 years, but it remains high in African regions and countries, as well as low-SDI areas. Effective cooperation among countries should be strengthened to improve the disease burden in high-burden areas and countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.